Stock listing

OTC:PTIX Protagenic Therapeutics, Inc. Stock

Follow Protagenic Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · OTC:PTIX

$0.38 USD -0.07 (-15.6%)

Close on Nov 20, 2026

Past year -81.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.353 – $0.48 USDNov 20, 2026
Volume
15,513 sharesNov 20, 2026
Market cap
$687,879 USDAt the close on Nov 20, 2026 · price × 1.81M shares outstanding
52-week range
$0.128 – $2.38 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$10,037 USDMedian day 1,300 shares · 7 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Protagenic Therapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:PTIX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.38-0.07-15.6%$0.405$0.48$0.35315,513
$0.45-0.008-1.6%$0.45$0.45$0.45500
$0.458+0.008+1.7%$0.458$0.458$0.4581,062
$0.45-0.022-4.6%$0.45$0.45$0.45601
$0.4720.000.0%$0.472$0.472$0.472502
$0.472-0.038-7.5%$0.472$0.472$0.472104
$0.510.000.0%$0.51$0.51$0.51790
$0.51-0.025-4.8%$0.53$0.53$0.513,000
$0.536-0.005-0.8%$0.54$0.54$0.5361,104
$0.54-0.09-14.3%$0.63$0.63$0.5367,501
$0.630.000.0%$0.63$0.63$0.63134
$0.63-0.02-3.1%$0.63$0.63$0.63139
$0.65+0.03+4.8%$0.66$0.66$0.651,000
$0.62-0.018-2.8%$0.62$0.62$0.621,006
$0.638-0.008-1.2%$0.638$0.638$0.6382,700
$0.646-0.007-1.1%$0.648$0.648$0.6421,700
$0.6530.000.0%$0.653$0.653$0.6530
$0.653+0.005+0.8%$0.653$0.653$0.653100
$0.648-0.072-10.0%$0.72$0.72$0.6483,500
$0.72-0.015-2.0%$0.72$0.72$0.72900
$0.735+0.015+2.1%$0.735$0.735$0.735500
$0.72-0.03-4.0%$0.72$0.72$0.72100
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.763$0.763$0.751,300
$0.750.000.0%$0.75$0.75$0.750
$0.75-0.05-6.3%$0.75$0.75$0.75200
$0.80-0.006-0.7%$0.80$0.80$0.80800
$0.8060.000.0%$0.806$0.806$0.8061,100
$0.806+0.036+4.7%$0.75$0.806$0.751,000
$0.770.000.0%$0.77$0.77$0.770
$0.770.000.0%$0.77$0.77$0.770
$0.770.000.0%$0.77$0.77$0.770
$0.77-0.004-0.5%$0.786$0.786$0.772,000
$0.7740.000.0%$0.774$0.774$0.7740
$0.774-0.006-0.8%$0.78$0.78$0.7741,200
$0.78-0.03-3.7%$0.80$0.801$0.785,700
$0.81+0.002+0.2%$0.832$0.832$0.81900
$0.808+0.028+3.6%$0.82$0.82$0.8081,200
$0.78+0.006+0.8%$0.774$0.78$0.774300
$0.774-0.042-5.1%$0.805$0.805$0.7744,100
$0.816-0.044-5.1%$0.816$0.816$0.8161,300
$0.860.000.0%$0.87$0.87$0.862,400
$0.86-0.046-5.1%$0.865$0.884$0.86800
$0.906-0.008-0.9%$0.914$0.93$0.9063,400
$0.914+0.185+25.4%$0.73$0.914$0.7333,500
$0.729-0.111-13.2%$0.769$0.769$0.72910,300
$0.84+0.05+6.3%$0.77$0.84$0.7653,300
$0.79-0.04-4.8%$0.81$0.81$0.7911,400
$0.83-0.041-4.7%$0.808$0.85$0.8086,700
$0.8710.000.0%$0.81$0.871$0.81400
$0.871-0.049-5.3%$0.90$0.90$0.813,100
$0.92-0.106-10.3%$0.91$0.938$0.8528,100
$1.026-0.034-3.2%$1.00$1.09$0.9025,800
$1.06+0.06+6.0%$0.95$1.06$0.951,700
$1.00-0.05-4.8%$1.02$1.02$0.9510,700
$1.05-0.14-11.8%$1.19$1.19$1.0517,700
$1.19-0.01-0.8%$1.225$1.24$1.1326,200
$1.20+0.22+22.4%$1.11$1.23$1.1130,100
$0.98+0.045+4.8%$0.935$1.11$0.93545,800
$0.935+0.045+5.1%$0.85$0.935$0.7736,600
$0.89-0.06-6.3%$0.95$1.01$0.86418,000
$0.95-0.14-12.8%$1.18$1.20$0.8543,400
$1.09+0.289+36.1%$0.85$1.32$0.85115,600
$0.801+0.201+33.5%$0.649$0.91$0.63140,600
$0.60+0.25+71.4%$0.40$0.613$0.4040,700

Splits

4 splits since 2007 · OTC:PTIX · every price before a split is adjusted for it

DayRatioWhat
1-for-14Consolidation
1-for-4Consolidation
1-for-4Consolidation
1-for-300Consolidation
Ticker
OTC:PTIX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Protagenic Therapeutics, Inc. news

Protagenic Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in the last 12 months · 1 in all · newest Nov 11, 2026 · oldest 2026
Calls
1 call with a replay · 1 with a transcript · latest Apr 1, 2024
Decks
4 decks · latest August 2021

Valuation

Price/book 0.6× against a median of 0.2×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$610,970 USD
P/E
0.1×
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.21

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Protagenic Therapeutics, Inc. · OTC:PTIXUS$687,879US$610,9700.1×n/an/a0.6×n/a0.0×1.21
Valion Bio, Inc. · NASDAQ:VBIOUS$1.04MUS$16.34Mn/a42.8×n/a0.2×n/a4.1×1.11
GeoVax Labs, Inc. · NASDAQ:GOVXUS$985,460−US$915,033n/an/an/a0.9×n/a0.2×1.47
Biodexa Pharmaceuticals plc · NASDAQ:BDRXUS$982,950−US$3.22Mn/an/an/a0.1×n/a0.0×1.01
Gabather AB · OMXSTO:GABAUS$919,514US$559,105n/an/an/a6.4×n/a0.0×n/a
ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2US$792,634−US$2.43Mn/a−6.5×n/a0.2×−935.9%0.0×n/a
Silexion Therapeutics Corp · NASDAQ:SLXNUS$790,001−US$3.60Mn/an/an/a0.3×n/a0.1×2.77
Oragenics Inc. · AMEX:OGENUS$708,377−US$1.12Mn/an/an/a0.7×n/a0.4×1.47
Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABTUS$580,337−US$2.74Mn/an/an/a0.2×n/a0.0×0.46
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
Median of the othersUS$791,318−US$1.30M−0.1×0.2×−558.9%0.1×1.36

Team and board

OfficerRole
Andrew SleeChief Development Officer

Events

Calls

CallWhenStatus
Protagenic Therapeutics (OTC:PTIX) Q4 2023 Earnings CallMon, Apr 01, 2024 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q2 2027Nov 17, 20260.0%
Q1 2027Aug 31, 2026+21.4%
Q4 2026Jun 3, 20260.0%
Q3 2026Feb 25, 2026+9.4%
Q2 2026Nov 26, 2025−4.5%
Q1 2026Aug 29, 2025+1.1%
Q4 2025May 13, 2025 · After close−6.5%
Q3 2025Mar 31, 2025 · Before open−13.3%
Q2 2025Nov 12, 2024 · After close−18.8%
Q1 2025Aug 14, 2024 · After close−15.6%
All 20 quarters
QuarterResultsShare move
Q4 2024May 15, 2024 · After close+7.2%
Q2 2024Nov 14, 2023 · After close0.0%
Q1 2024Aug 14, 2023 · After close0.0%
Q4 2023May 15, 2023 · After close−9.6%
Q4 2022Mar 31, 2023 · After close+4.6%
Q2 2023Nov 14, 2022 · After close−0.4%
Q1 2023Aug 11, 2022 · After close−1.9%
Q4 2022Apr 7, 2022 · After close+0.2%
Q4 2021Mar 2, 2022−3.2%
Q2 2022Nov 15, 2021 · After close−2.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2021)Investor deck28 slidesAugust 2021
Protagenic Therapeutics, Inc.\new — Investor Presentation (April 2021)Investor deck28 slidesApr 21, 2021
Protagenic Therapeutics, Inc.\new — Investor Presentation (April 2021)Investor deck28 slidesApr 8, 2021
Traffix — Merger or Acquisition (December 2007)Merger or acquisition30 slidesDec 5, 2007

Open Decks

Financings

RaiseDate
Private placement of shares of common stock, pre-funded warrants and common warrants
Announced: US$1.5M–US$5M · two series of milestone-linked warrants that may provide up to $3.5 million in… · Brookline Capital Markets, a division of Arcadia Securities, LLC
Dealers: Brookline Capital Markets, a division of Arcadia Securities, LLC (lead)
Use of proceeds: Complete IND-enabling activities for PT00114, start its Phase 1/2a trial in Generalized Anxiety Disorder, and working capital and general corporate purposes
Nov 11, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2025FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue000000000
Cost of revenue37.7K50.3K28.2K30286339347
Gross profit-37.7K-50.3K-28.2K-30-286-339-347
Research and development901.9K1.70M376.7K3.84M3.06M1.59M1.14M699.8K807.9K881.2K
Selling, general and administrative1.70M1.76M1.21M1.97M3.00M1.85M1.28M1.43M
Operating income-4.50M-5.83M-2.59M-5.70M-4.53M-3.56M-4.14M-2.55M-2.09M-2.31M
Depreciation and amortization49.2K37.7K50.3K28.2K30427286339347
EBITDA-4.45M-5.79M-5.65M-4.50M-3.56M-4.14M-2.55M-2.09M-2.31M
Interest expense296.9K0107.7K137.5K496.9K246.2K15.9K2.79K
Income before tax1.37M-5.16M-3.59M-5.53M-5.00M-3.56M-4.52M-2.55M-1.75M-2.56M
Income tax246.1K463.7K246.2K15.9K486.8K
Net income1.37M-5.16M-3.59M-5.53M-5.00M-3.56M-4.52M-2.55M-1.75M-2.56M
Earnings per share, basic0.59-2.66-0.67-1.13-1.15-0.82-1.24-0.25-0.17-0.25
Earnings per share, diluted0.59-0.67-1.13-1.15-0.82-0.31-0.25-0.17-0.25

Balance sheet

LineFY2026FY2025FY2025FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents1.51M2.21M14.5K1.84M1.29M215.2K541.2K671.1K798.6K362.5K
Short-term investments02.77M7.76M9.83M0250.4K250.4K
Receivables41.5K
Inventory1.07K1.04K0
Current assets1.54M2.30M89.1K1.88M4.20M8.04M11.1M879.2K842.0K696.3K
Property, plant and equipment14.6K60.5K73.0K123.3K1.77K296611
Goodwill0
Total assets3.65M2.13M89.1K1.96M4.32M8.04M11.1M879.2K842.3K696.9K
Accounts payable949.5K2.03M961.1K103.0K113.8K155.5K279.0K141.9K163.0K10.0K
Current liabilities1.03M6.82M5.04M942.8K655.3K1.12M799.5K655.2K1.20M907.8K
Long-term debt318.4K1.37M279.4K0
Total debt3.16M344.2K318.4K1.37M279.4K
Total liabilities1.03M6.82M5.04M942.8K655.3K1.12M1.12M2.03M1.48M907.8K
Shareholders' equity2.62M-2.39M-4.95M-3.32M3.67M6.92M9.94M-1.15M-634.4K-210.9K
Shares outstanding1.81M1.93M5.80M517.3K4.44M4.32M4.30M10.4M10.3M10.3M

Cash flow

LineFY2026FY2025FY2025FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-2.81M-4.14M-1.77M-4.22M-3.70M-1.99M-2.80M-1.35M-488.0K-1.07M
Capital spending-3.30K-30-149.8K-1.80K-4000
Free cash flow-2.81M-4.14M-4.22M-3.85M-2.00M-2.80M-1.35M-488.0K-1.07M
Cash from investing629.9K943.2K2.80M4.78M1.60M-9.91M-9.91M250.0K1.05M
Cash from financing3.87M4.51M1.81M1.96M0012.6M1.22M670.0K670.0K
Dividends paid0
Share buybacks0
Change in cash1.70M4.46M40.4K550.6K1.07M-326.0K-129.9K-127.5K436.1K-37.2K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 17, 2026Material contractSEC
10-Q · Quarterly reportNov 6, 2026Quarterly reportSEC
8-K · Current reportNov 6, 2026Material contractSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
8-K · Current reportAug 20, 2026Current reportSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
10-Q · Quarterly reportAug 19, 2026Quarterly reportSEC
NT 10-Q · Late filing noticeAug 14, 2026Explanation requestSEC
10-K · Annual reportAug 14, 2026Annual reportSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
NT 10-K · Late filing noticeJun 30, 2026Explanation requestSEC
8-K · Current reportApr 6, 2026Management or board changeSEC
10-Q · Quarterly reportMar 9, 2026Quarterly reportSEC
8-K · Current reportMar 2, 2026Management or board changeSEC
8-K · Current reportFeb 23, 2026Acquisition or disposalSEC
NT 10-Q · Late filing noticeFeb 18, 2026Explanation requestSEC
25-NSEJan 23, 2026Other filingsSEC
8-K · Current reportJan 5, 2026Current reportSEC
DEF 14A · Proxy statementDec 5, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 26, 2025Quarterly reportSEC
8-K · Current reportNov 26, 2025Current reportSEC
NT 10-Q · Late filing noticeNov 14, 2025Explanation requestSEC
8-K · Current reportNov 5, 2025Management or board changeSEC
8-K · Current reportOct 31, 2025Current reportSEC
424B5 · ProspectusOct 24, 2025Offer documentSEC
3 · Initial statement of ownershipOct 24, 2025Insider tradeSEC
8-K/A · Current report, amendedSep 17, 2025Current reportSEC
10-QTSep 10, 2025Other filingsSEC
8-K/A · Current report, amendedAug 27, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 25, 2025Big-stake noticeSEC
8-K · Current reportAug 22, 2025Current reportSEC
NT 10-Q · Late filing noticeAug 14, 2025Explanation requestSEC
8-K · Current reportAug 13, 2025Management or board changeSEC
8-K · Current reportJul 30, 2025Current reportSEC
8-K · Current reportJul 24, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJul 8, 2025Big-stake noticeSEC
8-K · Current reportJun 27, 2025Current reportSEC
8-K · Current reportMay 21, 2025Current reportSEC
8-K · Current reportMay 20, 2025Material contractSEC
DEFA14A · Additional proxy materialMay 19, 2025Meeting noticeSEC
8-K · Current reportMay 19, 2025Acquisition or disposalSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025Current reportSEC
8-K · Current reportApr 29, 2025Current reportSEC
8-K · Current reportApr 18, 2025Meeting outcomeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
DEF 14A · Proxy statementMar 7, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementFeb 27, 2025Meeting noticeSEC
8-K · Current reportFeb 24, 2025Management or board changeSEC
8-K · Current reportFeb 21, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportJan 29, 2025Current reportSEC
8-K · Current reportJan 15, 2025Current reportSEC
8-K · Current reportJan 10, 2025Material contractSEC
424B5 · ProspectusJan 10, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 10, 2025Other filingsSEC
CORRESP · Letter to the SECJan 7, 2025Other filingsSEC
S-3/A · Registration statement, amendedJan 7, 2025Offer documentSEC
DEFA14A · Additional proxy materialJan 6, 2025Meeting noticeSEC
DEF 14A · Proxy statementJan 3, 2025Meeting noticeSEC
CORRESP · Letter to the SECDec 30, 2024Other filingsSEC
424B3 · ProspectusDec 27, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 27, 2024Other filingsSEC
CORRESP · Letter to the SECDec 23, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 20, 2024Other filingsSEC
CORRESP · Letter to the SECDec 20, 2024Other filingsSEC
S-1 · Registration statementDec 20, 2024Offer documentSEC
PRE 14A · Preliminary proxy statementDec 19, 2024Meeting noticeSEC
8-K · Current reportDec 3, 2024Current reportSEC
8-K · Current reportNov 22, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 5, 2024Current reportSEC
8-K · Current reportOct 29, 2024Material contractSEC
8-K · Current reportSep 17, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportJul 26, 2024Current reportSEC
UPLOAD · Letter from the SECJun 18, 2024Other filingsSEC
S-3 · Registration statementJun 14, 2024Offer documentSEC
8-K · Current reportMay 24, 2024Current reportSEC
8-K · Current reportMay 22, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
10-K/A · Annual report, amendedMay 14, 2024Annual reportSEC
10-K/A · Annual report, amendedApr 23, 2024Annual reportSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
4 · Change in ownershipMar 29, 2024Insider tradeSEC
8-K · Current reportMar 21, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
8-K · Current reportDec 15, 2023Meeting outcomeSEC
8-K · Current reportNov 29, 2023Current reportSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
DEF 14A · Proxy statementNov 2, 2023Meeting noticeSEC
4 · Change in ownershipOct 13, 2023Insider tradeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
10-K/A · Annual report, amendedApr 17, 2023Annual reportSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
8-K · Current reportMar 22, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
8-K · Current reportNov 28, 2022Meeting outcomeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
DEF 14A · Proxy statementOct 11, 2022Meeting noticeSEC
8-K · Current reportSep 2, 2022Current reportSEC
10-Q · Quarterly reportAug 11, 2022Quarterly reportSEC
8-K · Current reportJun 29, 2022Current reportSEC
4 · Change in ownershipMay 18, 2022Insider tradeSEC
10-Q · Quarterly reportMay 13, 2022Quarterly reportSEC
10-K · Annual reportApr 7, 2022Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2022Explanation requestSEC
S-8 · Registration statement for employee plansMar 8, 2022Offer documentSEC
SC 13G · Big-stake noticeFeb 14, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 4, 2022Big-stake noticeSEC
10-Q · Quarterly reportNov 15, 2021Quarterly reportSEC
8-K · Current reportOct 5, 2021Current reportSEC
8-K · Current reportOct 1, 2021Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveSep 20, 2021Other filingsSEC
CORRESP · Letter to the SECSep 14, 2021Other filingsSEC
S-3/A · Registration statement, amendedSep 10, 2021Offer documentSEC
DEF 14A · Proxy statementSep 8, 2021Meeting noticeSEC
8-K · Current reportAug 18, 2021Current reportSEC
UPLOAD · Letter from the SECAug 18, 2021Other filingsSEC
10-Q · Quarterly reportAug 16, 2021Quarterly reportSEC
S-3 · Registration statementAug 13, 2021Offer documentSEC
8-K · Current reportJul 23, 2021Current reportSEC
8-K · Current reportJul 2, 2021Material contractSEC
424B5 · ProspectusJul 2, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 24, 2021Other filingsSEC
CORRESP · Letter to the SECJun 21, 2021Other filingsSEC
S-3/A · Registration statement, amendedJun 21, 2021Offer documentSEC
UPLOAD · Letter from the SECJun 11, 2021Other filingsSEC
S-3 · Registration statementJun 4, 2021Offer documentSEC
4 · Change in ownershipJun 3, 2021Insider tradeSEC
4 · Change in ownershipJun 1, 2021Insider tradeSEC
4 · Change in ownershipJun 1, 2021Insider tradeSEC
4 · Change in ownershipMay 20, 2021Insider tradeSEC
10-Q · Quarterly reportMay 17, 2021Quarterly reportSEC
4 · Change in ownershipMay 5, 2021Insider tradeSEC
4 · Change in ownershipMay 3, 2021Insider tradeSEC
8-K · Current reportApr 30, 2021Material contractSEC
424B4 · ProspectusApr 28, 2021Offer documentSEC
424B4 · ProspectusApr 28, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 27, 2021Other filingsSEC
S-1MEF · Registration of more shares for the same offeringApr 26, 2021Offer documentSEC
CERT · Exchange's certificate of listingApr 26, 2021Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeApr 26, 2021Other filingsSEC
S-1/A · Registration statement, amendedApr 26, 2021Offer documentSEC
S-1/A · Registration statement, amendedApr 23, 2021Offer documentSEC
CORRESP · Letter to the SECApr 23, 2021Other filingsSEC
CORRESP · Letter to the SECApr 23, 2021Other filingsSEC
S-1/A · Registration statement, amendedApr 23, 2021Offer documentSEC
CORRESP · Letter to the SECApr 22, 2021Other filingsSEC
CORRESP · Letter to the SECApr 22, 2021Other filingsSEC
8-K · Current reportApr 21, 2021Current reportSEC
CORRESP · Letter to the SECApr 21, 2021Other filingsSEC
CORRESP · Letter to the SECApr 21, 2021Other filingsSEC
S-1/A · Registration statement, amendedApr 9, 2021Offer documentSEC
8-K · Current reportApr 7, 2021Current reportSEC
S-1/A · Registration statement, amendedApr 7, 2021Offer documentSEC
10-K · Annual reportMar 25, 2021Annual reportSEC
S-8 · Registration statement for employee plansMar 10, 2021Offer documentSEC
UPLOAD · Letter from the SECFeb 22, 2021Other filingsSEC
S-1 · Registration statementFeb 11, 2021Offer documentSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2021Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2020Quarterly reportSEC
8-K · Current reportOct 7, 2020Meeting outcomeSEC
8-K · Current reportSep 3, 2020Material contractSEC
DEF 14A · Proxy statementAug 28, 2020Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2020Quarterly reportSEC
4 · Change in ownershipJul 21, 2020Insider tradeSEC
4 · Change in ownershipJul 21, 2020Insider tradeSEC
8-K · Current reportJul 21, 2020Management or board changeSEC
8-K · Current reportJul 9, 2020Material contractSEC
10-Q · Quarterly reportJun 18, 2020Quarterly reportSEC
8-K · Current reportMay 14, 2020Material contractSEC
8-K · Current reportMay 8, 2020Current reportSEC
10-K · Annual reportApr 28, 2020Annual reportSEC
8-K · Current reportMar 31, 2020Current reportSEC
S-8 · Registration statement for employee plansMar 11, 2020Offer documentSEC
8-K · Current reportMar 2, 2020Material contractSEC
SC 13D/A · Big-stake notice, amendedFeb 28, 2020Big-stake noticeSEC
4 · Change in ownershipFeb 26, 2020Insider tradeSEC
4 · Change in ownershipFeb 26, 2020Insider tradeSEC
4 · Change in ownershipFeb 26, 2020Insider tradeSEC
4 · Change in ownershipFeb 26, 2020Insider tradeSEC
4 · Change in ownershipFeb 26, 2020Insider tradeSEC
4 · Change in ownershipFeb 26, 2020Insider tradeSEC
5 · Annual statement of ownershipFeb 24, 2020Insider tradeSEC
5 · Annual statement of ownershipFeb 24, 2020Insider tradeSEC
8-K · Current reportJan 29, 2020Material contractSEC
UPLOAD · Letter from the SECJan 27, 2020Other filingsSEC

This page holds 200 of 708 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Protagenic Therapeutics, Inc.’s releases · as of Nov 11, 2026

Common shares
1,810,208
Fully diluted
1,810,208

Fully diluted

LineSharesAs of
Common shares1,810,208Nov 6, 2026

Share count over time

CountShares
Nov 6, 20261,810,208

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
DRW Securities, LLC41,7832.3%US$33,844Sep 30, 2026
FNY Investment Advisers, LLC25,0001.4%US$20Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Joshua N. Silverman
Other companies: Femasys Inc. (Director · Since at least Nov 21, 2023); PharmaCyte Biotech, Inc. (Interim Chief Executive Officer, President, and Director · Since at least Aug 15, 2022); TAO Synergies Inc. (Executive Chairman · Since at least Jun 4, 2021); Petros Pharmaceuticals Inc (Vice-Chairman of the Board · Since at least Dec 1, 2020); Q/C Technologies, Inc. (Executive Chairman · Since at least Sep 6, 2018); Fabric.AI, Inc. (Chief Executive Officer, Director · Since at least Aug 15, 2016); Marker Therapeutics, Inc. (Director · Nov 28, 2016 – Oct 16, 2018 · Past); Neurotrope Inc (Director · Aug 4, 2016 – Dec 1, 2020 · Past); MGT Capital Investments, Inc. (Director · Dec 31, 2015 – Dec 31, 2015 · Past); National Holdings Corporation (Director · Jul 28, 2014 – Sep 12, 2016 · Past)
Director · Feb 12, 2016 – Feb 21, 2020 · Past
Susan Swenson
Other companies: Faraday Future Intelligent Electric Inc. (Executive Chairperson, Director · Jul 21, 2021 – Jan 31, 2022 · Past); DNA X, Inc. (Director · May 9, 2019 – Nov 12, 2021 · Past); Vislink Technologies, Inc. (Director · Oct 19, 2018 – Feb 16, 2022 · Past); Inseego Corp. (Chief Executive Officer, Director · Jun 8, 2012 – May 12, 2017 · Past); Harmonic Inc. (Director · Feb 29, 2012 – Feb 15, 2024 · Past); Wells Fargo & Company (Director · Mar 21, 2006 – Apr 25, 2017 · Past)
Chief Operating Officer · Aug 20, 2007 – Dec 31, 2007 · Past
Alexander K Arrow
Other companies: EUDA Health Holdings Limited (Director · Nov 22, 2021 – Nov 22, 2021 · Past); 8I Enterprises Acquisition Corp (Director · Mar 27, 2019 – Mar 27, 2019 · Past)
Chief Financial Officer · Oct 16, 2017 – Mar 25, 2024 · Past
Brian Corvese
Other companies: MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021); Agenus Inc. (Director · Since at least Dec 17, 2020)
Director · Mar 25, 2024 – Mar 25, 2024 · Past
Jennifer Buell
Other companies: MiNK Therapeutics, Inc. (President and CEO · Since at least Oct 13, 2021); Agenus Inc. (President and CEO of MiNK Therapeutics and Chairman, Executive Council at Agenus · Since at least Jun 29, 2017)
Director · Jul 18, 2020 – Mar 25, 2024 · Past
Barrett Evans
Other companies: APPlife Digital Solutions, Inc. (CFO, Director · Since at least Jun 13, 2025)
ex CEO, Director · May 15, 2025 – May 15, 2025 · Past
Jay Wolf
Other companies: Digital Turbine, Inc. (Chief Financial Officer, Director · Oct 12, 2006 – Mar 4, 2009 · Past)
Director · Oct 24, 2006 – Oct 24, 2006 · Past
Jeffrey A Schwartz
Other companies: CarParts.com, Inc. (Director · Oct 22, 2007 – Jun 2, 2011 · Past)
Chief Executive Officer, Director · Nov 11, 2008 – Jan 27, 2010 · Past
Mark Dyne
Other companies: Talon International, Inc. (Director · Apr 22, 2008 – Sep 11, 2015 · Past)
Director · Nov 11, 2008 – Sep 28, 2010 · Past
Nathan Yu-Gai Fong
Other companies: Orchard Enterprises Inc (CFO · Feb 20, 2008 – Jul 29, 2010 · Past)
Chief Financial Officer · Sep 14, 2011 – Sep 14, 2011 · Past
All 15 people
PersonSeat
Robert Benjamin Stein
Other companies: PolyPid Ltd. (Director · Since at least Mar 18, 2026)
Director · Mar 25, 2024 – Mar 25, 2024 · Past
Andrew SleeChief Development Officer · Since at least Nov 5, 2026
Drew LarnerDirector · Feb 12, 2007 – Feb 17, 2007 · Past
Gregory EkizianDirector · Feb 12, 2016 – Jun 17, 2016 · Past
Khalil BarrageDirector · May 3, 2021 – Mar 25, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Protagenic Therapeutics, Inc.